#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl
#bl




     Ankieta  
 
Czy Polska ma jedne z najtańszych paliw w Europie?
 
   Informacje

SOPHARMA (SPH): Notification for acquisition of own shares (raport nr 110/2017)
07.12.2017 13:42


UNI - EN REPORT No110/2017

Sopharma AD hereby informs that on 6 December 2017 the Company bought 3 061 292 own shares representing 2.271% of the share capital of the Company, at a total value of 13 071 716.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

 

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.



The total number of treasury shares after these transactions is 9 146 785, representing 6.786% of the share capital of the Company. With these transactions Sopharma AD passed the threshold of 5% for the treasury shares.



(Emitent)

Załączniki:

   eko_7031673.zip
eko_7031673.zip

RSS - INTERIA.PL  Co to jest RSS ? »

 


 
 
   wyślij do znajomego « powrót  drukuj  
 


mWIG40    WIG    NIF
   KALENDARIUM
 
   31.05.2018 
WGPW  - Sesja giełdowa nie odbędzie się
   15.08.2018 
WGPW  - Sesja giełdowa nie odbędzie się
   01.11.2018 
WGPW  - Sesja giełdowa nie odbędzie się
   24.12.2018 
WGPW  - Sesja giełdowa nie odbędzie się
   25.12.2018 
WGPW  - Sesja giełdowa nie odbędzie się

  SPH: inne informacje
• Termination of the previous and start a new transformation procedure through the merger of Unipharm AD into Sopharma AD (raport nr 21/2018)
• Sales revenues for April 2018 (raport nr 20/2018)
• Invitation and materials for the General meeting of shareholders of Sopharma AD (raport nr 19/2018)
• Issued refusal by the Registry Agency on the transformation through merger between Sopharma AD and Unipharm AD (raport nr 18/2018)
• Annual audited consolidated financial report for 2017 (raport nr 17/2018)
• Financial report for the period ending 31.03.2018 (raport nr 16/2018)
• Notification concerning the General Meeting of Shareholders of Sopharma AD (raport nr 15/2018)
• Sales revenues for March 2018 (raport nr 14/2018)
• Annual audited individual financial statements of Sopharma AD for 2017 (raport nr 13/2018)
R E K L A M A